We sought to investigate the prognostic impact of co-morbid burden as defined by the Charlson Co-morbidity Index (CCI) in patients with a range of prevalent cardiovascular diseases.
Introduction
Cardiovascular disease (CVD) is a major cause of morbidity and mortality, accounting for 30% of all-cause mortality worldwide. 1 Given the incidence of CVD and co-morbidity burden increases with age, 2 a significant proportion of patients with CVD are older with multiple co-morbidities. This affects disease progression and clinical outcomes and can influence clinical decision-making. 3 -5 Cardiovascular co-morbidities such as hypertension, diabetes, atrial fibrillation, heart failure, and stroke have an independent association with increased mortality in patients hospitalized with acute myocardial infarction with increasing numbers of these co-morbidities particularly associated with poor outcomes. 6 While previous studies have mainly focused on cardiovascular comorbid conditions, patients with CVD often have a broad spectrum of non-cardiovascular co-morbidities. It remains unclear, however, how clustering of multiple cardiovascular and or non-cardiovascular chronic conditions influences clinical outcomes. Therefore, there is a need to understand the impact of co-morbid burden, rather than focusing on individual co-morbid conditions on clinical outcomes in patients with prevalent CVD. 2 The Charlson Co-morbidity Index (CCI) is a recognized measure of co-morbid burden 7 and quantifies the prognostic impact of 22 comorbid conditions based on their number and individual prognostic impact by means of a score. 8 It is a useful tool for estimating prognosis in patients with multiple coexisting illnesses. Table 1 represents the variables. Although various studies have evaluated the prognostic value of CCI in predicting outcomes in different cohorts of patients with CVD, there is no systematic review of the literature that evaluates the prognostic value of CCI on mortality across a range of CVDs. In this systematic review, we sought to investigate the prevalence, and prognostic impact, of co-morbidity defined by the CCI score in patients with three major CVDs; coronary heart disease (CHD), heart failure, and cerebrovascular accident (CVA).
Methods

Study inclusion criteria
We included primary studies that evaluated the prognostic impact of comorbid burden defined by CCI in patients with CHD, acute or chronic heart failure, and CVA. Studies were considered for inclusion and detailed review if their abstract potentially met all three of the following criteria:
(1) Primary studies evaluating the impact of co-morbidity defined by CCI on adverse outcomes in patients with CVD.
(2) CVD was defined by CHD [comprising of patients undergoing percutaneous coronary intervention (PCI) or stable angina or acute coronary syndrome (ACS)], or acute or chronic heart failure, or cerebrovascular disease. (3) Adverse outcomes included mortality and major adverse cardiac events (MACE) at any length of follow-up.
We excluded studies that did not have results on outcomes defined by CCI score, but there was no restriction on the basis of language of study. We also excluded expert opinion and editorial reviews. We included conference abstracts to minimize publication bias.
Search strategy
We searched MEDLINE and EMBASE on July 2015 using the broad search terms: ('Charlson co-morbidity index' OR 'Charlson index' OR 'Charlson co-morbidity score' OR 'Charlson score') AND ('acute myocardial infarction' OR 'acute coronary syndrome' OR 'coronary heart disease' OR 'coronary artery disease' OR 'stroke' OR 'cerebrovascular disease' OR 'cerebrovascular accident' OR 'heart failure' OR 'cardiac failure') AND ('mortality' OR 'death' OR 'major adverse cardiovascular event' OR 'major adverse cardiac event' OR 'cardiovascular disease').
The search results were reviewed by two independent investigators (M.R. and C.S.K.) for studies that met the inclusion criteria, and relevant reviews were identified. Additional studies were retrieved by checking the bibliographies of included studies and relevant reviews.
Data extraction
Data were extracted from each study into preformatted tables generated in Microsoft Word. Data collected included year, country, number of participants, mean age of participants, percentage of male participants, participant inclusion criteria, follow-up assessment, lost to follow-up, and results of association between CCI and outcomes. With regards to quality assessment, we documented the design of the study, reliable method of ascertainment of outcomes, .10% loss to follow-up, and if there was any adjustment for potential confounders.
Data analysis
Meta-analysis for estimated pooled risk ratios (RR) was performed by the inverse variance method using a random-effects model on the software RevMan 5.3 (Nordic Cochrane Centre, København, Denmark). To reduce the risk of confounding associated with crude estimates, where available, we chose to pool the results from the most adjusted model, whereby results were expressed as pooled relative RR with accompanying 95% confidence intervals (CI). Statistical heterogeneity was assessed using the I 2 statistic, with values of 30 -60% representing a moderate level of heterogeneity. 9 For I 2 . 50%, we performed sensitivity analysis by systematic exclusion of studies and evaluated the effect on I 2 estimates (see Supplementary material online, Table S1 ). The primary analysis evaluated adverse outcomes with incremental increase in CCI, and secondary analysis was performed by considering higher group of CCI score vs. lower group of CCI score. In the final analysis, we excluded studies by the same research group over the same time period where there was the potential that the same participants were studied more than once. Where there were similar study participants, we chose the study with the largest sample size or highest adverse outcome event rate. We evaluated publication bias through Funnel plots and Egger's test where there were .10 studies in the analysis and no evidence of statistical heterogeneity as the power to detect publication bias was low for meta-analyses of 10 or fewer studies. 
Results
Description of included studies
A total of 35 11 -45 studies met the inclusion criteria. The process of study selection is shown in Figure 1 . The details of the studies' design and participants are described in Figure 2 . Diabetes and a history of previous myocardial infarction were the two most common conditions present in patients with CHD. Approximately 10% of the patients with heart failure had previous history of myocardial infarction (only reported in 6 studies out of the total 13) and 12% had a history of chronic obstructive pulmonary disease. Similarly, diabetes was the most prevalent co-morbidity in the patients with CVA cohort. Haematological malignancies such as lymphoma leukaemia and AIDS were the least frequent co-morbid conditions across all the cohorts studied.
Quality assessment of included studies
The quality of studies included is described in Table 3 . There was no loss to follow-up for 13 of the included studies. Twenty-two studies had ,10% loss to follow-up. 
Results of included studies
The characteristics of patients included in the studies and association of CCI score on outcomes are described in Table 4 .
Acute coronary syndrome In an ACS registry (AMIS registry), Jeger et al. 22 reported an increased risk of MACE (a composite endpoint of re-infarction, CVA, and/or death) over a 1-year follow-up period in patients with CCI score of ≥2. In another study, Nú ñez et al. 28 demonstrated that a higher CCI score was an independent predictor of mortality or acute myocardial infarction at 30 days and 1 year.
Stable coronary heart disease Two studies 14, 35 studied the relationship between incremental rise in CCI score and mortality in patients with stable CHD ( Figure 3B ), suggesting that incremental increases in CCI score were associated with worse outcomes (RR 1.38; 95% CI 1.29 -1.48; I 2 ¼ 0%).
Sachdev et al. 35 also reported that patients with a CCI score of 0 have better long-term survival (RR 1.88; 95% CI 1.48 -2.38). They also reported that almost half of the patients (49%) included in the cohort were disease free and had no co-morbidities (CCI ¼ 0).
Patients undergoing percutaneous coronary intervention
Lastly, five studies 16, 20, 25, 38, 44 reported impact of CCI on long-term survival in patients undergoing PCI, out of which four indicated that mortality increases with each point rise in CCI score (RR 1.21; 95% CI 1.12-1.31; I 2 ¼ 71%) ( Figure 3C ). Only Mamas et al. 25 reported about patients with no co-morbidities in their study.
Heart failure A total of 13 studies reported the influence of co-morbidity in 63 609 patients with an underlying diagnosis of heart failure. An increased risk of mortality (RR 1.21; 95% CI 1.13 -1.29;
was observed per point increase in CCI score among four studies. 13 27, 45 reported increased risk of death with higher co-morbid burden with hazard ratio of .1, but it was unclear how they are related to CCI score. Both studies Heart failure (HF) CCI score 0 -2 vs. 3-4 or
≥4
Time to mortality to a maximum of 3 years 3-year mortality: CCI score 0 -2: HR 1.00; CCI score 3 -4: HR 1.5 (0.7 -2.9); CCI score .4: were only available in abstract form and, therefore, not included in the final meta-analysis. More interestingly, Subramanian et al. 39 assessed the impact of incremental increase in CCI per 3 points in heart failure patients over 5 years, reporting increased risk of death (HR 1.39; 95% CI 1.16-1.67) with growing burden of co-morbidities.
Cerebrovascular accident
A total of four studies analysed the impact of CCI score on survival in patients with an acute CVA. Khawaja et al. 24 reported a no significant increased risk of death with incremental increase in CCI score (RR 1.05; 95% CI 0.91 -1.21). However, higher CCI score (.2) had significant impact on mortality (RR 3.80; 95% CI 1.20 -12.01; I 2 ¼ 84%) when compared with low CCI score (0-2).
Discussion
In this study, we evaluated the prevalence and prognostic impact of co-morbidities as defined by CCI in patients with CHD, heart failure, and CVA. We observed a significant burden of co-morbidity in patients with CVD-two-thirds of patients included in the analysis had at least one chronic condition. The most common cardiovascular co-morbid conditions identified in patients with CHD were diabetes and history of prior myocardial infarction, whereas chronic obstructive pulmonary disease and kidney disease were the most frequent non-cardiovascular conditions. To our knowledge, this is the first study to systematically show the impact of co-morbid burden as defined by CCI on survival in patients with CHD, heart failure, and CVA. We found that the presence of co-morbidities had a significant incremental prognostic impact in patients with a broad range of CVDs. CHD is the commonest CVD affecting one in seven people in USA 46 and UK every year. Patients with CHD are likely to have higher number of coexisting illnesses either in the form of prevalent cardiovascular risk factors such as diabetes and hypertension or in the form of direct manifestations of CHD such as prior myocardial infarction or heart failure. For instance, in one study, diabetes, hypertension, and heart failure were found to be most frequently encountered coexisting illnesses in patients admitted with ACS and 68% of the participants had at least three co-morbidities. 47 The rising burden of co-morbidity has been reported to have inverse relationship with survival outcomes in patients with CHD. In our analysis, incremental rise in CCI was associated with significant increase in mortality and the risk of death was almost doubled with the presence of any co-morbidity compared with the patients with no co-morbidity ( Figure 3A) . This has important clinical implications in this cohort of patients as the prevalent cardiovascular risk factors such as hyperlipidaemia, smoking, and other related cardiovascular co-morbidities such as hypertension and diabetes in patients with CHD are usually treated aggressively, but there is growing evidence that non-CVD burden may also contribute to increased risk of mortality. 25, 31 We report that CCI is not only a simple way of quantifying co-morbid burden but also provides prognostic value in ascertaining outcomes. Clinicians often use risk assessment tools such as GRACE and TIMI scores in determining Figure 3 Continued.
the type of intervention, treatment plan, and allocation of resources in managing patients with ACS. Although these models have been validated in predicting the adverse events, 48, 49 the clinical data incorporated in these models do not take into account the co-morbid burden of the patients. Previous studies have suggested that the performance of such risk models improves when co-morbidity scores such as CCI are added to the risk scores 17 and may help in better allocations of resources and developing robust treatment pathways for patients with multiple co-morbidities. Our study highlights the importance of taking into consideration of the overall comorbid burden in such patients while making the therapeutic decisions. Furthermore, our study also demonstrates that comorbidity burden has prognostic value. The prevalence of heart failure is increasing due to the ageing population and better survival from acute cardiac events. 50 Our findings reinforce the hypothesis that heart failure patients with multiple co-morbidities have worse outcomes. 15 Similarly, increasing co-morbid burden is associated with a worse prognosis in patients after an acute cerebrovascular event. We observed that the risk of death was almost four-fold greater in patients with two or more coexisting illnesses (Figures 4 and 5) .
The mechanism by which the coexisting co-morbid burden influences outcomes in patients with CVD is complex and multifactorial. Older and frailer patients with high burden of co-morbidities are more likely to be treated conservatively following a cardiovascular event. 51, 52 For instance, a large national ACS registry reported an incremental reduction in provision of evidence-based treatments such as aspirin, statins, angiotensin-converting enzyme (ACE) inhibitors, and reperfusion therapy to the older multi-morbid patients. 53 In another recent analysis of 18 814 patients, Patel et al. identified that patients with higher co-morbid burden as defined by CCI were less likely to receive coronary artery angiography and/or revascularization following presentation with ST-segment elevation myocardial infarction. 54 Similarly, thrombolysis therapy in acute ischaemic stroke is usually reserved for younger patients with no significant burden of co-morbidities due to fear of less favourable outcomes such as bleeding complications in elderly patients with multiple co-morbidities. 55 In the management of patients with chronic heart failure, the associated burden of co-morbidities may limit the use of medications such as ACE inhibitors or spironolactone, particularly in patients with severe chronic kidney disease 56 and b-blockers in patients with coexisting severe chronic obstructive pulmonary disease. Furthermore, patients with multiple chronic conditions are less likely to receive invasive therapies such as implantable cardioverter-defibrillators or cardiac resynchronization therapy. 57 There is also growing evidence that increasing burden of co-morbidities in patients with heart failure is associated with repeated hospitalization and poor outcomes. 58, 59 Provision of aggressive treatment strategies in patients with multimorbidity can lead to higher incidence of complications and adverse outcomes. For example, patients with leukaemia are at higher risk of stent thrombosis 60 and those with liver dysfunction are at increased Figure 4 Heart failure patients and mortality according to Charlson Co-morbidity Index.
risk of bleeding complications post-PCI and cardiac mortality. 61 Similarly, the presence of diabetes and haematological disorders has been shown to increase the risk of haemorrhagic transformation in patients with ischaemic stroke. 62, 63 Consequently, the presence of coexisting diseases may drive poor outcomes in patients with CHD due to reduced scope of treatment options and increased risk of complications. Hence, clinicians may be reserved in deciding treatment strategies while managing patients with multi-morbidity due to the challenge of finding a balance between risk and benefit of an intervention. 64, 65 Other factors that may be responsible for deleterious effect of co-morbidities on survival outcomes are the presence of coexisting illness sharing the same pathophysiology and adverse drug reactions due to polypharmacy. For example, the presence of anaemia results in low cardiac output state and has been reported to have synergetic impact on the mortality in patients with chronic heart failure. 66 Our findings have important implications in the management of patients with CHD, heart failure, and cerebrovascular disease. Treatment options such as medical therapies, PCI, surgical revascularization, device therapies, and thrombolysis are now readily available to wider spectrum of patients. Although international guidelines 67,68 advocate a comprehensive assessment of patients taking into account their co-morbid status, contemporary risk stratification tools such as GRACE, Cath PCI, and Syntax are derived from data sets based on patient's characteristics, procedural demographics, and cardiovascular risk factors and do not take into account patients' co-morbid burdens. Our analysis shows that CCI score has prognostic value in our cohort of patients and using CCI alongside these risk models can help physicians to ascertain outcomes and better resource allocation. For instance, the addition of CCI to the Mayo Clinic Risk Score for PCI increased net reclassification index by 34% and improved the c-statistic for the model significantly. 38 Erickson et al. 17 also tested the risk prediction of GRACE model by adding CCI and observed a significant improvement in predicting outcomes in ACS patients. Another study reported improved discriminative performance of GRACE Risk Prediction Index score when added with CCI in predicting future cardiac-related events post-myocardial infarction. 17 Therefore, the assessment of co-morbid status and its impact on long-term survival should be integrated into the counselling of the patients before deciding the choice of treatment in conjunction with traditional risk assessment. Our study has several strengths and limitations. To our knowledge, this is the first review on impact of co-morbidity defined by CCI on major CVD such as CHD, heart failure, and cerebrovascular disease. We were able to analyse the impact of per unit rise in CCI in our cohort of patients demonstrating that rise in CCI score has inverse relationship with survival. We were also able to evaluate the impact of CCI among individual cohorts of CHD namely stable angina, ACS, and those undergoing PCI and found a uniform negative impact of rising CCI score across all cohorts. Additionally, we also studied the prevalence of co-morbidities in patients with CVD and found that majority of patients in this cohort have significant burden of co-morbidities.
Our study was limited by the incomplete reporting of original studies and was reliant on the published data available. We were not able to evaluate the impact of individual components of CCI on mortality, as this was not consistently reported across all studies. Furthermore, the studies included in our review were mainly observational, which have their own inherent limitations and may be subject to selection biases and unmeasured confounders. Another limitation is that we found significant heterogeneity in several analyses. This may be because many of the studies are large with very narrow confidence intervals leading to statistical heterogeneity when there is little overlap in 95% CI among the studies. However, all the studies, in general, report estimates that are consistently significant and favour increased events with higher CCI score. The statistical heterogeneity arises from differences in each study in terms of population evaluated and study methodology, which leads to variation in estimates for the prognostic value of CCI.
Conclusion
Our study shows that co-morbid burden defined by CCI is significant across a broad range of cardiovascular conditions and has significant impact on survival in patients with CHD, heart failure, and CVA. Assessment of co-morbid burden using CCI provides a method of quantifying risk associated with co-morbidities in patients with CVD and should be incorporated into decision-making processes when counselling patients regarding risk and benefits of treatment in conjunction with allocation of resources.
